Meeting
2019 Gastrointestinal Cancers Symposium
Impact of new chemotherapy regimens on the treatment landscape and survival of advanced pancreatic cancer (PAC) patients (pts).
Authors
Markus Kieler
Medical University of Vienna, Vienna, Austria
Markus Kieler , Matthias Unseld , Daniela Bianconi , Werner Scheithauer , Gerald W. Prager
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 403)
DOI
10.1200/JCO.2019.37.4_suppl.403
Abstract #
403
Poster Bd #
M3
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
First-line chemotherapy regimens associated with survival in advanced pancreatic cancer: A Mexican single-center, real-world study.
First Author: Marytere Herrera
Poster
2018 Gastrointestinal Cancers Symposium
Second-line treatment of modified FOLFIRINOX or nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma.
First Author: Masato Ozaka
Poster
2017 Gastrointestinal Cancers Symposium
Determinants of first-line treatment selection in advanced pancreatic ductal adenocarcinoma (PDAC).
First Author: Hui-Li Wong
Poster
2014 ASCO Annual Meeting
Use of first-line chemotherapy for advanced pancreatic cancer: FOLFIRINOX versus gemcitabine-based therapy.
First Author: Thomas H. Cartwright